114 related articles for article (PubMed ID: 38528728)
61. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
[TBL] [Abstract][Full Text] [Related]
62. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure.
Löfsjögård J; Kahan T; Díez J; López B; González A; Edner M; Henriksson P; Mejhert M; Persson H
J Cardiovasc Med (Hagerstown); 2014 Jun; 15(6):463-9. PubMed ID: 24983265
[TBL] [Abstract][Full Text] [Related]
63. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
[TBL] [Abstract][Full Text] [Related]
64. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Xiang Y; Shi W; Li Z; Yang Y; Wang SY; Xiang R; Feng P; Wen L; Huang W
Medicine (Baltimore); 2019 Mar; 98(13):e14967. PubMed ID: 30921200
[TBL] [Abstract][Full Text] [Related]
66. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
67. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.
Buckley LF; Canada JM; Del Buono MG; Carbone S; Trankle CR; Billingsley H; Kadariya D; Arena R; Van Tassell BW; Abbate A
ESC Heart Fail; 2018 Apr; 5(2):372-378. PubMed ID: 29345112
[TBL] [Abstract][Full Text] [Related]
68. Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology.
Gąsiorek P; Sakowicz A; Banach M; von Haehling S; Bielecka-Dabrowa A
Dis Markers; 2019; 2019():9636197. PubMed ID: 31612072
[TBL] [Abstract][Full Text] [Related]
69. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
[TBL] [Abstract][Full Text] [Related]
70. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
[TBL] [Abstract][Full Text] [Related]
71. Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3.
Zivlas C; Triposkiadis F; Psarras S; Giamouzis G; Skoularigis I; Chryssanthopoulos S; Kapelouzou A; Ramcharitar S; Barnes E; Papasteriadis E; Cokkinos D
Ther Adv Cardiovasc Dis; 2017 Nov; 11(11):283-295. PubMed ID: 28830298
[TBL] [Abstract][Full Text] [Related]
72. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
73. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
74. Plasma natriuretic peptide levels reflect changes in heart failure symptoms, left ventricular size and function after surgical mitral valve repair.
Feringa HH; Poldermans D; Klein P; Braun J; Klautz RJ; van Domburg RT; van der Laarse A; van der Wall EE; Dion RA; Bax JJ
Int J Cardiovasc Imaging; 2007 Apr; 23(2):159-65. PubMed ID: 16941223
[TBL] [Abstract][Full Text] [Related]
75. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
[TBL] [Abstract][Full Text] [Related]
76. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Verdonschot JAJ; Ferreira JP; Pizard A; Pellicori P; Brunner La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Waring OJ; Henkens MHTM; Mariottoni B; Petutschnigg J; Rossignol P; Hazebroek MR; Cleland JGF; Zannad F; Heymans SRB;
J Card Fail; 2022 May; 28(5):778-786. PubMed ID: 34933097
[TBL] [Abstract][Full Text] [Related]
77. Relation of N-Terminal Pro-B-Type Natriuretic Peptide and Left Ventricular Diastolic Function to Exercise Tolerance in Patients With Significant Valvular Heart Disease and Normal Left Ventricular Systolic Function.
Hwang JW; Park SJ; Cho EJ; Kim EK; Lee GY; Chang SA; Choi JO; Lee SC; Park SW
Am J Cardiol; 2017 Jun; 119(11):1846-1853. PubMed ID: 28391990
[TBL] [Abstract][Full Text] [Related]
78. An altered plasma lipidome-phenome network characterizes heart failure with preserved ejection fraction.
Jovanovic N; Foryst-Ludwig A; Klose C; da Conceicao CR; Alasfar L; Birkner T; Forslund SK; Kintscher U; Edelmann F
ESC Heart Fail; 2024 Jun; 11(3):1553-1566. PubMed ID: 38243357
[TBL] [Abstract][Full Text] [Related]
79. Prognostic Value of Left Atrial Functional Measures in Heart Failure With Reduced Ejection Fraction.
Modin D; Sengeløv M; Jørgensen PG; Olsen FJ; Bruun NE; Fritz-Hansen T; Andersen DM; Jensen JS; Biering-Sørensen T
J Card Fail; 2019 Feb; 25(2):87-96. PubMed ID: 30472280
[TBL] [Abstract][Full Text] [Related]
80. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
